Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS

Transcription

1 Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS

2 Survival Rates of by Stage of Adenocarcinoma of the Colon

3 Liver Resection New Perspective

4 Colorectal cancer liver metastases Disease is limited to the liver: Unresectable liver metastases: Chemotherapy Low number of patients are cured Neoadjuvant or induction chemotherapy followed by resection if response: conversion therapy If resectable: 20-30% of cure rate Chemotherapy + RFA? (other local treatments??) Resectable liver metastases: Resection with neoadjuvant and/or adjuvant chemotherapy 25-40% of patients are cured

5 Future Liver Remnant Volume (FLR)

6 Future Liver Remnant Volume (FLR)

7

8 Resection of metastases: an optimal treatment goal

9 Survival after liver resection: 10,940 patients Resectable vs initially non-resectable

10 Survival in patients undergoing surgery Overall survival probability in relation to response to preoperative chemotherapy in 4,851 patients undergoing a first resection of colorectal liver metastases

11 Unresectable CRC metastases Aim of chemotherapy is to render unresectable metastases resectable Choose best regimen to convert unresectable metastases: Achieve high response rate Clinically manageable with minimal toxicity The long term survival of patients who undergo complete resection after conversion of initially unresectable liver metastases approaches the survival of patients with initially resectable metastases Need for multidisciplinary discussions (expert surgeons, GI oncologists, radiologists, etc) before and after chemotherapy

12 Which regimen should be used as conversion treatment? OPTIONS: FOLFIRI and FOLFOX are likely to be equally effective Triple drug combinations such as FOLFOXIRI superior to FOLFIRI (RR 60% vs 34%, R0 resection 36% vs 12%) Not confirmed in Greek Study (Souglakis et al, Brit J Cancer 2006) Many phase 2 studies with promising data FOLFIRI or FOLFOX plus cetuximab (KRAS wild type) FOLFIRI or FOLFOX plus bevacizumab FOLFOXIRI + biological

13 FOLFOXIRI + biologic Phase III TRIBE study: FOLFIRI/bev vs FOLFOXIRI/bev as first-line therapy for mcrc 1 N = 508 PFS: 9.7 vs 12.2 mo (HR: 0.73 [ ] p = ) RR: 53 vs 65% (p = 0.006) FOLFIRINOX + cetuximab 2 Preliminary evaluation: high activity

14 Colorectal cancer liver metastases Disease is limited to the liver: Unresectable liver metastases Resectable liver metastases Resection: 5 years survival 25-40% Neoadjuvant and/or adjuvant chemotherapy Pre- and postoperative FOLFOX (3 + 3 months) Postoperative IV 5-FU/LV Postoperative intrahepatic ± IV chemotherapy Postoperative FOLFIRI Postoperative FOLFOX (6 months) No published data on lung metastases: identical attitude (extrapolation of the data)

15 OncoSurgical strategies in liver metastases: from palliative to curative

16 Conclusions Patients with metastatic CRC can be cured, if resection is possible Chemotherapy can downsize unresectable metastases and may allow resection of unresectable liver metastases: conversion concept. Cure can also be obtained in these patients. Correlation between response rate and resection rate Response to chemotherapy leads to better outcome Most active regimen should be proposed in unresectable CRC metastases Resectable metastases: should be resected combination of 2 cytotoxics (FOLFOX) perioperative or postoperative MULTIDISCIPLINARY EXPERT TEAM

17 BRAF Mutations in CRC BRAF is the primary effector of KRAS signaling BRAF mutations: Only in KRAS wt Portends poor prognosis

18 WHAT DIAGNOSTIC TESTS? KRAS BRAF UGT1A1 polymorphism VEGF-A EGF-R P53 PI3K

19

20 Neoadjuvant Chemotherapy

21

22 Multimodality Management of CRC Liver Metastases Neoadjuvant chemotherapy Resectable liver metastases Facilitate surgery Obtain predictive and prognostic information Early systemic therapy for poor-prognosis pts Conversion chemotherapy Unresectable liver metastases Allow R0 resection via downsizing Postoperative (adjuvant) chemotherapy Hepatic arterial infusion (HAI) Systemic treatment

23 FIRE-3

24 Similar Survival After Primary or Secondary Resection of Liver Metastases

25

26

27

28

29 Treatment-Associated Liver Toxicity 5-FU: steatosis Irinotecan: steatohepatitis Oxaliplatin: sinusoidal/vascular injury Bevacizumab Potential wound healing complications Need to wait 6-8 wks before surgical resection Cetuximab: no acute or chronic effects to date Incidence of postoperative complications increases with prolonged use

30 Conversion Therapy: Practical Issues FOLFOXIRI attractive but at expense of increased toxicity Limit duration of preoperative therapy to 3-4 mos Treat to resectability and not to best response Minimizes hepatotoxicity Role of biologics is evolving Data with cetuximab appears to be most mature in wild-type KRAS CRC Bevacizumab is an appropriate option in setting of mutant KRAS If bevacizumab is used, discontinue 6-8 wks before planned surgery

31 Advanced Disease: Standard Biological Targets in mcrc Angiogenesis Cancers need new vasculature to grow beyond a certain size [1] Erratic/irregular blood vessel growth with leaky, poorly formed vasculature [2] Key molecular target VEGF promotes tumor angiogenesis [3] Epidermal growth factor receptor (EGFR) Hetero- or homodimerization leads to activation of multiple downstream pathways including Ras/RAF/MEK/ERK and PI3K/AKT [4] Results in proliferation, survival, angiogenesis, and metastasis [4]

32 RF

33 Radioembolization

34 SRS or Radiation Therapy

35 SRS